Kovack Advisors’s Rein Therapeutics RNTX Stock Holding History

Kovack Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-750	Closed	-$7K	–	758
2022 Q1	$7K	Buy	+750	New	+$6.79K	﹤0.01%	718

Other funds holding RNTX

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

TCA

Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Kovack Advisors's RNTX Position: Q2 2022 in Review

Kovack Advisors sold out of Rein Therapeutics (RNTX) in Q2 2022, closing a stake of 750 shares — an estimated $7K sold.

Kovack Advisors first reported a position in RNTX in Q1 2022 and held it in 1 quarter. The position peaked at $7K in Q1 2022. 37 funds tracked by Wall St. Rank hold RNTX as of Q2 2022.

Kovack Advisors reported no remaining Rein Therapeutics position as of Q2 2022 after selling out during the quarter.
Kovack Advisors sold 750 Rein Therapeutics shares in Q2 2022, an estimated $7K.
Kovack Advisors first reported a position in Rein Therapeutics in Q1 2022 and held it in 1 quarter.
Kovack Advisors's Rein Therapeutics position peaked at $7K in Q1 2022.
37 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2022.

Based on Kovack Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.